Figure 2

Bryostatin reactivates latent HIV-1 infection via activation of classical and novel PKCs.
(a) NHA and (c) U-87 cells were pretreated with bryostatin either alone or in combination with a classical PKC inhibitor GF109203X (10 μM) or the novel PKC inhibitor rottlerin (5 μM) as indicated and monitored using ELISA. The mean values (mean ± S.D.) of three independent experiments are shown. (b) The d10/d8 dpi ratio of NHA cells. (d) The d10/d8 dpi ratio of U-87 cells. The results of three independent experiments expressed as the fold increase relative to that of infected cells.